Phase II
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
Researchers found fear of testing new treatments and possible side effects were common denominators among patients.
No more patients will be enrolled in the trials and current treatment “will cease” while they determine the risks and plans for the trials.
Companies from across the globe provide updates on their pipelines and business.
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.
ACE-083 was the company’s lead product candidate for its neuromuscular therapeutic program.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
PRESS RELEASES